Skip to main content
Erschienen in: Cancer Causes & Control 2/2016

01.02.2016 | Original paper

Body mass index and weight change in relation to triple-negative breast cancer survival

verfasst von: Ping-Ping Bao, Hui Cai, Peng Peng, Kai Gu, Yinghao Su, Xiao-Ou Shu, Ying Zheng

Erschienen in: Cancer Causes & Control | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the influence of body mass index (BMI), weight change on triple-negative breast cancer (TNBC) prognosis in a population-based prospective cohort study. The current analysis included 518 participants diagnosed with TNBC in Shanghai Breast Cancer Survival Study. Weight at 1 year prior to cancer diagnosis, at diagnosis, and at 6, 18 and 36 months after cancer diagnosis and height at 6 months after cancer diagnosis were assessed. Disease-free survival (DFS) and overall survival (OS) were evaluated in relation to BMI and weight change using Cox proportional hazard models. Obesity (BMI ≥ 28.0 kg/m2) at 1-year pre-diagnosis was associated with higher risk of total mortality and recurrence/disease-specific mortality, with multivariate hazard ratios (HRs) of 1.79 (95 % CI 1.06–3.03) and 1.83 (95 % CI 1.05–3.21), respectively. The associations between BMI and TNBC prognosis attenuated over time from pre-diagnosis to post-diagnosis. Compared with stable weight (change within 5 %), weight loss ≥5 % at 18- or 36-month post-diagnosis was related with higher risk of total mortality and recurrence/disease-specific mortality. Respective multivariate HRs were 2.08 (95 % CI 1.25–3.46) and 1.42 (95 % CI 0.77–2.63) for OS, and 2.50 (95 % CI 1.45–4.30) and 2.17 (95 % CI 1.14–4.12) for DFS. However, the association of weight loss and OS/DFS attenuated after excluding patients whose weight was measured after recurrence. Weight gain ≥5 % at 18- or 36-month post-diagnosis was associated with a non-significant increased risk of death. The results showed that obesity pre-diagnosis and weight loss post-diagnosis was inversely associated with TNBC prognosis. Emphasis on maintaining stable weight after cancer diagnosis for TNBC patients may be considered.
Literatur
1.
Zurück zum Zitat Conroy SM, Maskarinec G, Wilkens LR, White KK, Henderson BE, Kolonel LN (2011) Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study. Breast Cancer Res Treat 129:565–574PubMedPubMedCentralCrossRef Conroy SM, Maskarinec G, Wilkens LR, White KK, Henderson BE, Kolonel LN (2011) Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study. Breast Cancer Res Treat 129:565–574PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123:627–635PubMedCrossRef Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123:627–635PubMedCrossRef
3.
Zurück zum Zitat Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH (2013) Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 24:2506–2514PubMedPubMedCentralCrossRef Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH (2013) Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 24:2506–2514PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Kwan ML, Chen WY, Kroenke CH et al (2012) Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 132:729–739PubMedPubMedCentralCrossRef Kwan ML, Chen WY, Kroenke CH et al (2012) Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 132:729–739PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Azrad M, Demark-Wahnefried W (2014) The association between adiposity and breast cancer recurrence and survival: a review of the recent literature. Curr Nutr Rep 3:9–15PubMedPubMedCentralCrossRef Azrad M, Demark-Wahnefried W (2014) The association between adiposity and breast cancer recurrence and survival: a review of the recent literature. Curr Nutr Rep 3:9–15PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901–1914PubMedPubMedCentralCrossRef Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901–1914PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(Suppl 6):vi7–vi12PubMedCrossRef Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(Suppl 6):vi7–vi12PubMedCrossRef
8.
Zurück zum Zitat Ademuyiwa FO, Groman A, O’Connor T, Ambrosone C, Watroba N, Edge SB (2011) Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer 117:4132–4140PubMedCrossRef Ademuyiwa FO, Groman A, O’Connor T, Ambrosone C, Watroba N, Edge SB (2011) Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer 117:4132–4140PubMedCrossRef
9.
Zurück zum Zitat Sparano JA, Wang M, Zhao F et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118:5937–5946PubMedPubMedCentralCrossRef Sparano JA, Wang M, Zhao F et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118:5937–5946PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Mowad R, Chu QD, Li BD, Burton GV, Ampil FL, Kim RH (2013) Does obesity have an effect on outcomes in triple-negative breast cancer? J Surg Res 184:253–259PubMedCrossRef Mowad R, Chu QD, Li BD, Burton GV, Ampil FL, Kim RH (2013) Does obesity have an effect on outcomes in triple-negative breast cancer? J Surg Res 184:253–259PubMedCrossRef
11.
Zurück zum Zitat Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX (2014) Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat 146:189–197PubMedCrossRef Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX (2014) Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat 146:189–197PubMedCrossRef
12.
Zurück zum Zitat Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM (2012) Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer 12:364–372PubMedCrossRef Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM (2012) Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer 12:364–372PubMedCrossRef
13.
Zurück zum Zitat Pajares B, Pollan M, Martin M et al (2013) Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res 15:R105PubMedPubMedCentralCrossRef Pajares B, Pollan M, Martin M et al (2013) Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res 15:R105PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Turkoz FP, Solak M, Petekkaya I et al (2013) The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J BUON 18:335–341PubMed Turkoz FP, Solak M, Petekkaya I et al (2013) The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J BUON 18:335–341PubMed
15.
Zurück zum Zitat Makari-Judson G, Braun B, Jerry DJ, Mertens WC (2014) Weight gain following breast cancer diagnosis: implication and proposed mechanisms. World J Clin Oncol 5:272–282PubMedPubMedCentralCrossRef Makari-Judson G, Braun B, Jerry DJ, Mertens WC (2014) Weight gain following breast cancer diagnosis: implication and proposed mechanisms. World J Clin Oncol 5:272–282PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Nichols HB, Trentham-Dietz A, Egan KM et al (2009) Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 18:1403–1409PubMedPubMedCentralCrossRef Nichols HB, Trentham-Dietz A, Egan KM et al (2009) Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 18:1403–1409PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Thivat E, Therondel S, Lapirot O et al (2010) Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer 10:648PubMedPubMedCentralCrossRef Thivat E, Therondel S, Lapirot O et al (2010) Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer 10:648PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Bradshaw PT, Ibrahim JG, Stevens J et al (2012) Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. Epidemiology 23:320–327PubMedPubMedCentralCrossRef Bradshaw PT, Ibrahim JG, Stevens J et al (2012) Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. Epidemiology 23:320–327PubMedPubMedCentralCrossRef
19.
20.
Zurück zum Zitat Caan BJ, Kwan ML, Shu XO et al (2012) Weight change and survival after breast cancer in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev 21:1260–1271PubMedPubMedCentralCrossRef Caan BJ, Kwan ML, Shu XO et al (2012) Weight change and survival after breast cancer in the after breast cancer pooling project. Cancer Epidemiol Biomarkers Prev 21:1260–1271PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Jeon YW, Lim ST, Choi HJ, Suh YJ (2014) Weight change and its impact on prognosis after adjuvant TAC (docetaxel–doxorubicin–cyclophosphamide) chemotherapy in Korean women with node-positive breast cancer. Med Oncol 31:849PubMedCrossRef Jeon YW, Lim ST, Choi HJ, Suh YJ (2014) Weight change and its impact on prognosis after adjuvant TAC (docetaxel–doxorubicin–cyclophosphamide) chemotherapy in Korean women with node-positive breast cancer. Med Oncol 31:849PubMedCrossRef
22.
Zurück zum Zitat Caan BJ, Kwan ML, Hartzell G et al (2008) Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control 19:1319–1328PubMedPubMedCentralCrossRef Caan BJ, Kwan ML, Hartzell G et al (2008) Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control 19:1319–1328PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Su Y, Zheng Y, Zheng W et al (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 11:292PubMedPubMedCentralCrossRef Su Y, Zheng Y, Zheng W et al (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 11:292PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Matthews CE, Shu XO, Yang G et al (2003) Reproducibility and validity of the Shanghai Women’s Health Study physical activity questionnaire. Am J Epidemiol 158:1114–1122PubMedCrossRef Matthews CE, Shu XO, Yang G et al (2003) Reproducibility and validity of the Shanghai Women’s Health Study physical activity questionnaire. Am J Epidemiol 158:1114–1122PubMedCrossRef
27.
Zurück zum Zitat Grunau GL, Sheps S, Goldner EM, Ratner PA (2006) Specific comorbidity risk adjustment was a better predictor of 5-year acute myocardial infarction mortality than general methods. J Clin Epidemiol 59:274–280PubMedCrossRef Grunau GL, Sheps S, Goldner EM, Ratner PA (2006) Specific comorbidity risk adjustment was a better predictor of 5-year acute myocardial infarction mortality than general methods. J Clin Epidemiol 59:274–280PubMedCrossRef
28.
Zurück zum Zitat Korn EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145:72–80PubMedCrossRef Korn EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145:72–80PubMedCrossRef
29.
Zurück zum Zitat Rock CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20:3302–3316PubMedPubMedCentralCrossRef Rock CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20:3302–3316PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Demark-Wahnefried W, Campbell KL, Hayes SC (2012) Weight management and its role in breast cancer rehabilitation. Cancer 118:2277–2287PubMedCrossRef Demark-Wahnefried W, Campbell KL, Hayes SC (2012) Weight management and its role in breast cancer rehabilitation. Cancer 118:2277–2287PubMedCrossRef
31.
Zurück zum Zitat Cole SW (2009) Chronic inflammation and breast cancer recurrence. J Clin Oncol 27:3418–3419PubMedCrossRef Cole SW (2009) Chronic inflammation and breast cancer recurrence. J Clin Oncol 27:3418–3419PubMedCrossRef
32.
Zurück zum Zitat Oh SW, Park CY, Lee ES et al (2011) Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res 13:R34PubMedPubMedCentralCrossRef Oh SW, Park CY, Lee ES et al (2011) Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res 13:R34PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Dodson S, Baracos VE, Jatoi A et al (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62:265–279PubMedCrossRef Dodson S, Baracos VE, Jatoi A et al (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62:265–279PubMedCrossRef
34.
Zurück zum Zitat Zauderer M, Patil S, Hurria A (2009) Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat 117:205–210PubMedCrossRef Zauderer M, Patil S, Hurria A (2009) Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat 117:205–210PubMedCrossRef
Metadaten
Titel
Body mass index and weight change in relation to triple-negative breast cancer survival
verfasst von
Ping-Ping Bao
Hui Cai
Peng Peng
Kai Gu
Yinghao Su
Xiao-Ou Shu
Ying Zheng
Publikationsdatum
01.02.2016
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 2/2016
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-015-0700-7

Weitere Artikel der Ausgabe 2/2016

Cancer Causes & Control 2/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.